Ultragenyx Pharmaceutical, Inc. RARE 深 滬
等待開盤 09-08 09:30:00 美东时间
15.30
+0.450
+3.03%
華盛通- 最 高16.0799
- 今 開15.475
- 成交量 1149.44万股
- 最 低 15.23
- 昨 收 14.85
- 總市值 15.08亿
- 52周最高 39.8899
- 市盈率 靜 --
- 換手率 11.66%
- 52周最低 13.81
- 委 比 96.49%
- 總股本 9858.89万
- 歷史最高 179.647
- 量 比 1.45
- 振 幅 5.72%
- 歷史最低 13.81
- 每 手 1
- 風險率 4.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Red Cat, USA Rare Earth, uniQure, Ultragenyx, Copart Trending
Analysts are intrested in these 5 stocks: ( ($RCAT) ), ( ($USAR) ), ( ($QURE) )...
09-05 17:01
美股周涨跌榜 | 生物医药企业SMMT周涨逾28%！关键药物取得突破；加密货币概念股齐升，IREN周内大涨26%
生物医药企业SMMT周涨逾28%！关键药物取得突破；加密货币概念股齐升，IREN周涨26%！受比特币反弹及云业务双重催化；Strive涨近25%，四天增持约1,800枚比特币>>
09-05 10:16
Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $19
Goldman Sachs analyst Salveen Richter maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $28 to $19.
09-05 01:57
美股大行评级 | 大行齐上调AI应用股目标价！Adobe、CRWD等获看好，慧与科技绩后现多空分歧
今日重点评级关注：BTIG：维持Climb Bio"买入"评级，目标价从20美元升至32美元；巴克莱：维持Alpha Tau Medical"超配"评级，目标价从17美元升至30美元
09-04 12:30
QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target
Martin Shkreli, known as Pharma Bro, said Ultragenyx Pharmaceutical (NASDAQ:RARE) is undervalued and a potential takeover target for rare-disease peers like BioMarin Pharmaceuticals (NASDAQ:BMRN) after a trial setback. He said "$RARE is very cheap" and urged BioMarin and other rare-disease companies...
09-04 00:17
Ultragenyx Forced To Cut Costs After Disappointing Phase 3 Results
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stock is tumbling on Thursday after reporting late-stage clinical trial failures for its Angelman syndrome therapy, apazunersen, prompting the biopharmaceutical firm to review the program’s future and plan significant corporate expense reductions. Underst...
09-03 21:10
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. cut the price target for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) from $50 to $25. HC W...
09-03 20:35
NetApp, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Thursday. Shares of NetApp, Inc. (NASDAQ:NTAP) fell sharply in pre-market trading following first-quarter results. NetApp reported quarterly earnings of $2.58 per share, which beat the consensus estimate o...
09-03 20:02
Market-Moving News for September 3rd
AVGO: -5% | AVGO stock has given up its prior loss. Broadcom shares were trading lower after the company reported Q3 financial results and issued Q4 sales guidance below estimates. SNOW: -23% | Snowflake shares are trading higher after the company reported better-than-expected Q2 financial results...
09-03 19:14
Ultragenyx FDA-Approved Treatment Shows Sustained Reduction in Cornstarch Intake
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) on Wednesday announced the publication of 96-week Phase 3 trial data evaluating its gene therapy GENGLYCOS, also known as DTX401, for patients with glycogen storage disease type Ia (GSDIa). Published in The Journal of Inherited Metabolic Disease, the long...
09-02 22:41
